PhD defence: David Haldrup
Weight Loss Following Gastric Bypass or Semaglutide: Effects on Body Composition and Hepatic Lipid Metabolism
Info about event
Time
Location
Verdensrummet (A201-170), Steno Diabetes Center Aarhus, Aarhus University Hospital
On Friday 27 November at 13:00, David Haldrup defends his PhD dissertation entitled “Changes in body composition and hepatic lipid and glucose metabolism following extensive weight loss and improvement of MASLD induced by Roux-en-Y gastric bypass or semaglutide”.
Severe obesity is closely associated with fatty liver disease and disturbances in hepatic lipid metabolism. Both gastric bypass and semaglutide induce substantial weight loss, but it remains unclear if these treatments affect body composition, liver fat, and hepatic lipid metabolism differently.
In his PhD project, David Haldrup compared the two treatments in a randomised trial involving 22 women with severe obesity and fatty liver disease. Participants were examined before, in the early and the late phase of the weight loss, with assessments of body composition, liver fat, and lipid and glucose metabolism using advanced tracer techniques.
Overall, the findings suggest that the magnitude of weight loss, rather than the type of treatment, is the primary determinant of changes in body composition and hepatic lipid metabolism, and describe how the hepatic lipid and glucose metabolism adapts to extensive weight loss.
The summary is written by the PhD student.
The defence is public and takes place in Verdensrummet (A201-170), Steno Diabetes Center Aarhus, Aarhus University Hospital. Please see the press release for more information.
Contact
PhD student David Haldrup
Mail: david.haldrup@clin.au.dk
Phone: +45 20912152